Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

Not Applicable

Terminated

• Conditions: Central Serous Chorioretinopathy
• Interventions: Other: No treatment; Device: Micropulse Laser Treatment

• Registration Number: NCT01982383
• Lead Sponsor: George Washington University

Brief Summary

The investigators hypothesis is that using the micropulse laser in patient with Central Serous Chorioretinopathy (CSC) will prompt resolution of CSC and will be effective in significantly minimizing visual recovery time from this disease as well as potentially preventing recurrences.

Detailed Description

The investigators hypothesize that application of 577nm micropulse laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence tomography and best corrected visual acuity. This will be a pilot study to establish sound methods and provide some insights to the safety and efficacy of CSC treatment.

Study Timeline

• Study Start: 2012-11
• Study First Submitted: 2013-11-06
• Study First Submitted QC: 2013-11-12
• Study First Posted: 2013-11-13
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Status Verified: 2018-03
• Results First Submitted: 2018-03-01
• Results First Submitted QC: 2018-03-01
• Last Update Submitted: 2018-03-01
• Results First Posted: 2018-03-27
• Last Update Posted: 2018-03-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Patients with new diagnosis of CSC and no other comorbidities or prior retinal treatment
• Patients ranging from 30 to 60 years of age

Exclusion Criteria

• Patients with no case of CSC
• Patients with other macular comorbidities including but not limited to diabetic retinopathy, macular degeneration
• Patients with prior retinal treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
No Treatment	No treatment	Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
Micropulse Laser Treatment	Micropulse Laser Treatment	Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine

Primary Outcome Measures

Name	Time	Method
Resolution of Fluid Build-up	within 1 week to 3 months after the laser procedure is completed	Central Serous Choroidopathy is a disease that causes fluid to build up under the retina,the back part of the inner eye that sends sight information to the brain. The objective here is to apply 577nm of micropulse laser to see if CSC resolution occurs and measuring it through ocular coherence tomography (retinal imaging), vision score, and visual field testing for retinal sensitivity.

Trial Locations

Locations (1)

George Washington University Medical Faculty Associates; 🇺🇸 Washington, District of Columbia, United States